Deadline Alert: RxSight, Inc. (RXST) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Core Viewpoint - RxSight, Inc. is facing a class action lawsuit due to significant declines in sales and revenue, leading to a substantial drop in stock price following the release of disappointing financial results for Q2 2025 [2][3]. Financial Performance - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in LDD sales, LAL utilization, and overall revenue [2]. - The company lowered its full year 2025 guidance by approximately $42.5 million at the midpoint [2]. - Following the announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, with unusually heavy trading volume [2]. Lawsuit Details - The class action lawsuit alleges that during the Class Period, RxSight's management made materially false and misleading statements and failed to disclose adverse facts about the company's business and prospects [3]. - Specific allegations include: (1) the company faced "adoption challenges" leading to declines in sales and utilization; (2) overstated demand for RxSight's products; (3) unlikelihood of meeting previously issued financial guidance for fiscal year 2025; (4) positive statements about the company's business were materially misleading [3]. Legal Actions - Investors who purchased or acquired RxSight securities during the Class Period can file a lead plaintiff motion by September 22, 2025 [4].